Edesa Biotech (EDSA) cleared by FDA to add sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for ARDS

Go back to Edesa Biotech (EDSA) cleared by FDA to add sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for ARDS
(NASDAQ: EDSA) Delayed: 6.01 +0.14 (2.39%)
Previous Close $5.87    52 Week High
Open $5.88    52 Week Low
Day High $6.09    P/E N/A 
Day Low $5.87    EPS
Volume 119,114